Alkermes plc. - 8-K Filing
Alkermes reports positive phase 1b results showing ALKS 7290's clinical proof-of-concept as an orexin 2 receptor agonist in treating ADHD. (Items: 7.01 Regulation FD Disclosure, 8.01 of this Current Report on Form 8-K, 9.01 Financial Statements and Exhibits)
Tickers: $ALKS